-
The justices struggled to decide whether to give a thumbs up or thumbs down to the multibillion dollar Purdue Pharma bankruptcy deal -- a deal meant to compensate victims of OxyContin.
-
In exchange for giving up ownership of drug manufacturer Purdue Pharma and for contributing up to $6 billion to fight the crisis, members of the wealthy Sackler family would be exempt from any civil lawsuits
-
Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.
-
A federal appeals court reversed a 2021 ruling that found bankruptcy court judges did not have the authority to shield from civil lawsuits members of the Purdue owners.
-
The DOJ is seeking to block implementation of any part of the Purdue Pharma bankruptcy deal until legal challenges are settled. The deal granted Sackler family members immunity from opioid lawsuits.
-
The decision by a federal bankruptcy judge grants members of the family who own Purdue Pharma, maker of OxyContin, sweeping protection from any liability for the opioid crisis.
-
A group of state attorneys general negotiating with members of the Sackler family says they expect Purdue Pharma to file for bankruptcy "imminently," according to an email obtained by NPR.